B-Cell-Tailored Dosing of Ocrelizumab Yields Encouraging Results
Patients with relapsing-remitting MS showed promising results with B-cell-tailored dosing of ocrelizumab.
Read MoreInsights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.